CF
CRGX

Cantor Fitzgerald’s CARGO Therapeutics CRGX Stock Holding History

Cantor Fitzgerald’s Portfolio CRGX Stock Details CRGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-96,972
Closed -$395K – 476
2025
Q1 		$395K Buy
+96,972
New +$649K 0.01% 166

Other funds holding CRGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $136M AUM 328.39% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return

Cantor Fitzgerald's CRGX Position: Q2 2025 in Review

Cantor Fitzgerald sold out of CARGO Therapeutics (CRGX) in Q2 2025, closing a stake of 96,972 shares — an estimated $395K sold.

Cantor Fitzgerald first reported a position in CRGX in Q1 2025 and held it in 1 quarter. The position peaked at $395K in Q1 2025. 116 funds tracked by Wall St. Rank hold CRGX as of Q2 2025.

  • Cantor Fitzgerald reported no remaining CARGO Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 96,972 CARGO Therapeutics shares in Q2 2025, an estimated $395K.
  • Cantor Fitzgerald first reported a position in CARGO Therapeutics in Q1 2025 and held it in 1 quarter.
  • Cantor Fitzgerald's CARGO Therapeutics position peaked at $395K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held CARGO Therapeutics as of Q2 2025.

Based on Cantor Fitzgerald's 13F filing for Q2 2025, filed 14 Aug 2025.